Alexander German asks since we can’t fix every failure mode of human biology yet, what if we paused the organism instead?
Being young and healthy is universally desirable. Retaining and restoring youth and health has fascinated humankind from mythology to modern science. As early as the 17th century, Robert Boyle included it among his “desiderata” – his scientific wish list.
Today, longevity and rejuvenation research attract more attention than ever. Promising evidence is emerging from animal models, but translating these interventions to humans looks long and bumpy. The aging process is deeply baked into our biology.
For many people alive today, the only way to benefit from future breakthroughs may be technologies that act as a pause button – what I summarise here as medical hibernation. Dormant states may sound less appealing than eternal youth, but they are an equally persistent theme, from mythology to science fiction.
Medical hibernation is also a natural endpoint for cryobiology, a field that can be traced back to Boyle himself. Compared with reversing aging outright, human-scale cryobiology may be technically more achievable – and much of its potential remains untapped.
Why curing aging is so hard
In the 19th century, scientists discovered that human mortality data between ages 20 and 90 could be fitted remarkably well with the Gompertz–Makeham law. This equation shows that something as complex as aging can be captured by a surprisingly simple formula. Yet, more than a century later, we still lack a complete mechanistic explanation.
Over the last two centuries, medicine has succeeded in driving down the age-independent hazard – the constant risk that comes from infection, accident or disease. We have become experts at fixing single points of failure: replacing insulin in type 1 diabetes, clotting factors in hemophilia, removing tumours surgically, eliminating bacteria with antibiotics.
But we have not yet reduced the age-dependent hazards – the parameters that govern how risk of death accelerates with time. True longevity interventions would need to prevent or delay a broad range of conditions: hypertension, heart failure, type 2 diabetes, neurodegeneration and the many cascading failures of aging itself.
For each species, these parameters reflect an evolutionary trade-off between early reproductive success and long-term maintenance. This antagonistic pleiotropy, combined with damage accumulation and other mechanisms, makes aging almost as complex as the organism itself. Experiments such as caloric restriction, mTOR inhibition, parabiosis, senolytics and stem cell reprogramming show it can be modulated, but comprehensive rejuvenation would require targeting thousands of failure points that evolution has left unresolved.
Even if we discovered a miracle longevity pill, residual baseline risks – from accidents to random disease – would remain. Hence, medical hibernation offers a pragmatic fallback: not a cure for aging, but a way to buy time until cures arrive.
Why hibernation could be medicine’s pause button
Throughout the second half of the 20th century, cryobiology has quietly achieved remarkable things – from species conservation to stem cell transplantation and reproductive medicine. Recent work has demonstrated a rat kidney that was vitrified, rewarmed and successfully transplanted with life-sustaining function. Scaling this technology to larger organs – and eventually whole organisms – may be more attainable than defeating aging itself.
There are three main reasons:
- Pausing a complex system is easier than repairing it.
- Nature shows it can be done. Arctic ground squirrels and other hibernators recover from deep hypothermic-hypometabolic arrest.
- Vitrification creates new possibilities. Turning tissues into cryogenic glass, already used for embryos and rodent organs, enables states far beyond natural limits – an untapped opportunity space, orthogonal to evolutionary optimisation.
We don’t need to reach full medical hibernation to reap benefits. The ability to preserve and distribute viable human cells and tissues would unlock a new paradigm for biomedical research – particularly in aging, where standardised, time-stable human biomaterial is scarce. Scaling to whole organs could transform transplantation from emergency to elective medicine. Ultimately, scaling to the organism might expand our options not only in trauma care, but even in how humanity moves through time and space.
What comes next
Reversible medical hibernation may be more tractable than comprehensive rejuvenation, but it remains a formidable challenge. Important work still lies ahead – from theoretical modelling to empirical testing, from studying natural hibernators to understanding cryoprotectant toxicity and the psychology of dormancy.
One way to contribute is through the Organ Hibernation Challenge, supported by Renaissance Philanthropy and the German Agency for Breakthrough Innovation (SPRIND). Details HERE.
About Alexander German
Alexander German, MD, is a clinician-scientist at the Department of Molecular Neurology, University Erlangen-Nuremberg, and co-founder of Hiber. His clinical research and startup focus on structural brain preservation; his basic research explores cryopreservation of the brain.
